Suppr超能文献

最佳治疗的结直肠转移的生存结果:肝和腹膜表面疾病的手术治疗中 R0 状态的重要性。

Survival Outcomes of Optimally Treated Colorectal Metastases: The Importance of R0 Status in Surgical Treatment of Hepatic and Peritoneal Surface Disease.

机构信息

Department of General Surgery, Division of Surgical Oncology, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA.

Mayo Clinic Florida, Jacksonville, FL, USA.

出版信息

Ann Surg Oncol. 2023 Jul;30(7):4264-4273. doi: 10.1245/s10434-023-13174-3. Epub 2023 Feb 8.

Abstract

BACKGROUND

Although colorectal hepatic metastases (HM) and peritoneal surface disease (PSD) are distinct biologic diseases, they may have similar long-term survival when optimally treated with surgery.

METHODS

This study retrospectively reviewed prospectively managed databases. Patients undergoing R0 or R1 resections were analyzed with descriptive statistics, the Kaplan-Meier method, and Cox regression. Survival was compared over time for the following periods: 1993-2006, 2007-2012, and 2013-2020.

RESULTS

The study enrolled 783 HM patients undergoing liver resection and 204 PSD patients undergoing cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Compared with PSD patients, HM patients more often had R0 resections (90.3% vs. 32.4%), less often had pre-procedure chemotherapy (52.4% vs. 92.1%), and less often were functionally independent (79.7% vs. 95.6%). The 5-year overall survival for HM was 40.9%, with a median survival period of 45.8 months versus 25.8% and 33.4 months, respectively, for PSD (p < 0.05). When stratified by resection status, R0 HM and R0 PSD did not differ significantly in median survival (49.0 vs. 45.4 months; p = 0.83). The median survival after R1 resection also was similar between HM and PSD (32.6 vs. 26.9 months; p = 0.59). Survival between the two groups again was similar over time when stratified by resection status. The predictors of survival for HM patients were R0 resection, number of lesions, intraoperative transfusion, age, and adjuvant chemotherapy. For the PSD patients, the predictors were peritoneal cancer index (PCI) score, estimated blood loss (EBL), and female gender.

CONCLUSION

The study showed that R0 resections are associated with improved outcomes and that median survival is similar between HM and PSD patients when it is achieved. Surveillance and treatment strategies that facilitate R0 resections are needed to improve results, particularly for PSD.

摘要

背景

尽管结直肠肝转移(HM)和腹膜表面疾病(PSD)是两种不同的生物学疾病,但当它们通过手术得到最佳治疗时,它们可能具有相似的长期生存。

方法

本研究回顾性分析了前瞻性管理数据库。对接受 R0 或 R1 切除术的患者进行描述性统计分析、Kaplan-Meier 方法和 Cox 回归分析。比较了以下三个时间段的生存情况:1993-2006 年、2007-2012 年和 2013-2020 年。

结果

该研究纳入了 783 例 HM 患者行肝切除术和 204 例 PSD 患者行细胞减灭术和腹腔热灌注化疗(HIPEC)。与 PSD 患者相比,HM 患者更常行 R0 切除术(90.3% vs. 32.4%),较少行术前化疗(52.4% vs. 92.1%),且功能性独立性较低(79.7% vs. 95.6%)。HM 的 5 年总生存率为 40.9%,中位生存时间为 45.8 个月,而 PSD 分别为 25.8%和 33.4 个月(p<0.05)。按切除术状态分层,R0 HM 和 R0 PSD 的中位生存时间无显著差异(49.0 与 45.4 个月;p=0.83)。R1 切除术后的中位生存时间在 HM 和 PSD 之间也相似(32.6 与 26.9 个月;p=0.59)。按切除术状态分层时,两组之间的生存时间再次相似。HM 患者的生存预测因素为 R0 切除术、病变数量、术中输血、年龄和辅助化疗。对于 PSD 患者,预测因素为腹膜癌指数(PCI)评分、估计失血量(EBL)和女性性别。

结论

该研究表明,R0 切除术与改善预后相关,当达到 R0 切除术时,HM 和 PSD 患者的中位生存时间相似。需要制定有助于实现 R0 切除术的监测和治疗策略,以改善结果,特别是对于 PSD。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验